1-Difluormethoxy-2,4-dimethyl-benzol | 772-22-5

• 英文名称: 1-Difluormethoxy-2,4-dimethyl-benzol
• 英文别名: 1-Difluoromethoxy-2,4-dimethylbenzene；1-(difluoromethoxy)-2,4-dimethylbenzene
• CAS: 772-22-5
• 化学式: C₉H₁₀F₂O
• 分子量: 172.175
• InChiKey: UIGNSICHXTXJJS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] NEW MACROLIDES AND THEIR USE<br/>[FR] NOUVEAUX MACROLIDES ET LEUR UTILISATION
  申请人：BASILEA PHARMACEUTICA AG

  公开号：WO2009106419A1

  公开（公告）日：2009-09-03

  The invention relates to macrolide compounds of formula (I),the use of said compounds as medicaments, in particular for the treatment or prevention of inflammatory and allergic diseases, pharmaceutical compositions containing said compounds and to processes for their preparation. The invention relates in particular to macrolide compounds with anti-inflammatory activity mediated primarily through inhibition of phosphodiesterase 4 (PDE4) which makes them useful for the treatment and/or prevention of inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, atopic dermatitis or inflammatory bowel disease or proliferative diseases such as cancer.

  本发明涉及公式(I)的大环内酯化合物，以及所述化合物作为药物的应用，特别是用于治疗或预防炎性和过敏性疾病，包含所述化合物的药物组合物，以及它们的制备过程。本发明特别涉及主要通过抑制磷酸二酯酶4（PDE4）介导抗炎活性的大环内酯化合物，这使得它们可用于治疗和/或预防诸如慢性阻塞性肺病（COPD）、哮喘、类风湿性关节炎、特应性皮炎、炎症性肠病或增殖性疾病，例如癌症等炎性和过敏性疾病。
• Selective NR2B Antagonists
  申请人：Bristol-Myers Squibb Company

  公开号：US20130079338A1

  公开（公告）日：2013-03-28

  The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, antagonists of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.

  该披露通常涉及到I式化合物，包括它们的盐，以及使用这些化合物的组合物和方法。这些化合物是NR2B受体的配体，是其拮抗剂，可能对治疗中枢神经系统的各种疾病有用。
• TUMOR TARGETED DRUG COMBRETASTATIN A4 DERIVATIVE
  申请人：Wang Yong

  公开号：US20140128384A1

  公开（公告）日：2014-05-08

  The present invention relates to imidazole, oxazole and thiazole derivatives of tumor-targeted drug combretastatin A4, and phosphate esters, sulfonate esters or pharmaceutically acceptable salts, glycoside derivatives, solvates thereof, wherein the A-ring comprises a 3,5-dimethoxyphenyl group having a substituent at the 4-position. The pharmacological activity assays have demonstrated that the compounds of the present invention have good in vitro anti-tumor activity and excellent tubulin inhibitory effect.

  本发明涉及肿瘤靶向药物康柏他丁A4的咪唑、噁唑和噻唑衍生物，以及磷酸酯、磺酸酯或药用可接受的盐、糖苷衍生物、其溶剂合物，其中A环包括在4位有取代基的3,5-二甲氧基苯基基团。药理活性测定表明，本发明的化合物在体外具有良好的抗肿瘤活性和优秀的微管抑制作用。
• CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：US20150057262A1

  公开（公告）日：2015-02-26

  The present invention provides compounds of Formula (Ia): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

  本发明提供了式(Ia)的化合物：或其立体异构体、互变异构体或药学上可接受的盐，其中所有变量均如本文所定义。这些化合物是选择性因子XIa抑制剂或FXIa和血浆卡利肽酶的双重抑制剂。本发明还涉及包含这些化合物的制药组合物以及使用它们治疗血栓栓塞和/或炎症性疾病的方法。
• BENZOPYRAZOLE COMPOUND USED AS RHO KINASE INHIBITOR
  申请人：Medshine Discovery Inc.

  公开号：EP3782987A1

  公开（公告）日：2021-02-24

  The invention relates to a benzopyrazole compound used as RHO kinase inhibitor, a pharmaceutical composition and uses thereof for preparing an RHO kinase inhibiting drug, and more specifically to said compound of formula (I-1), a pharmaceutically acceptable salt and isomer thereof.

  本发明涉及一种用作 RHO 激酶抑制剂的苯并吡唑化合物、制备 RHO 激酶抑制药物的药物组合物及其用途，更具体地说，涉及所述式（I-1）化合物、其药学上可接受的盐和异构体。